News articles about Fluidigm Corporation (NASDAQ:FLDM) have been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fluidigm Corporation earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 45.8780117171274 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Fluidigm and Ascendas Genomics Announce Strategic Partnership to Develop Microfluidic Molecular Diagnostics in China (finance.yahoo.com)
- Fluidigm Corporation (FLDM) Scheduled to Post Earnings on Thursday (americanbankingnews.com)
- Week 30 Breakout Forecast: Short-Term Picks To Give You An Edge (seekingalpha.com)
- Fluidigm : to Report Q2 2017 Financial Results and Host Conference Call (4-traders.com)
- Fluidigm Corporation (NASDAQ:FLDM) Experiences Lighter than Average Trading Volume (highlightpress.com)
Shares of Fluidigm Corporation (NASDAQ:FLDM) opened at 3.86 on Friday. The stock’s market cap is $113.08 million. Fluidigm Corporation has a 52 week low of $3.45 and a 52 week high of $10.94. The stock has a 50 day moving average price of $3.91 and a 200-day moving average price of $5.26.
Several analysts have weighed in on FLDM shares. Zacks Investment Research downgraded Fluidigm Corporation from a “buy” rating to a “hold” rating in a research note on Monday, April 10th. ValuEngine downgraded Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
In related news, Director Samuel D. Colella purchased 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The shares were purchased at an average price of $5.93 per share, for a total transaction of $44,475.00. Following the transaction, the director now directly owns 43,523 shares of the company’s stock, valued at approximately $258,091.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Evan/ Fa Jones sold 10,900 shares of the business’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $4.54, for a total value of $49,486.00. The disclosure for this sale can be found here. Insiders own 4.70% of the company’s stock.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
